Insider Transactions in Q1 2023 at Regenxbio Inc. (RGNX)
Insider Transaction List (Q1 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 03
2023
|
Patrick J. Christmas Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
67,940
+43.28%
|
-
|
|
Jan 03
2023
|
Patrick J. Christmas Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,843
-8.03%
|
$40,546
$22.68 P/Share
|
|
Jan 03
2023
|
Kenneth T. Mills |
BUY
Grant, award, or other acquisition
|
Direct |
54,753
+13.35%
|
-
|
|
Jan 03
2023
|
Kenneth T. Mills |
SELL
Payment of exercise price or tax liability
|
Direct |
9,308
-3.0%
|
$204,776
$22.68 P/Share
|
|
Jan 03
2023
|
Olivier Danos Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
65,930
+41.5%
|
-
|
|
Jan 03
2023
|
Olivier Danos Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,058
-7.08%
|
$45,276
$22.68 P/Share
|
|
Jan 03
2023
|
Steve Pakola Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
90,588
+46.85%
|
-
|
|
Jan 03
2023
|
Steve Pakola Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,138
-20.49%
|
$69,036
$22.17 P/Share
|
|
Jan 03
2023
|
Steve Pakola Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,837
-10.71%
|
$40,414
$22.68 P/Share
|
|
Jan 03
2023
|
Curran Simpson Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
67,945
+42.22%
|
-
|
|
Jan 03
2023
|
Curran Simpson Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,076
-7.66%
|
$45,672
$22.68 P/Share
|
|
Jan 03
2023
|
Vittal Vasista Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
46,174
+20.42%
|
-
|
|
Jan 03
2023
|
Vittal Vasista Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,333
-0.99%
|
$29,326
$22.68 P/Share
|